Williams on the Phase 3 SunRISe-2 Study of TAR-200/Cetrelimab in MIBC


Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.

At the 2024 American Urological Association (AUA) Annual Meeting, updates on the phase 3 SunRISe-2 study (NCT04658862) are being presented. SunRISe-2 is investigating TAR-200, an intravesical device, plus cetrelimab vs chemotherapy for the treatment of patients with muscle-invasive bladder cancer.

Here, study investigator Stephen Williams, MD, MBA, MS, FACS, FACHE, professor and chief of the Division of Urology, Department of Surgery at the University of Texas Medical Branch in Galveston, TX, discusses TAR-200 and the study being presented as part of the Clinical Trials in Progress program at the AUA Annual Meeting.


0:05 | So TAR-200 Is the intravesical device which eludes chemotherapy and includes gemcitabine. Really, this is a device that's installed within the office by a urologist. And then importantly and concomitantly, in the TAR-200 SunRISe-2 trial, you know, we work in a multidisciplinary manner, where we want to compare this treatment with cetrelimab, depending upon the trials, of course, or the stage of the disease vs other conventional treatments.

0:35 | [SunRISe-2] is a phase 3, randomized, controlled, trial multicenter, multinational, which really is wonderful, because we've identified patients with muscle-invasive bladder cancer that are either cystectomy ineligible or refusing cystectomy that would like to understand bladder sparing options. And particularly, we're comparing TAR-200 plus cetrelimab vs trimodal therapy, which is including chemotherapy with systemic therapy as well.

Related Videos
Thomas Powles, MBBS, MRCP, MD, with Rohit Gosain, MD, and Rahul Gosain, MD, presenting slides
Related Content